Lytix Biopharma

📍 Oslo, Norway🗓 Founded 2003👥 23 employees💰 Last funded Jun 2015
Biotechnology🌐 lytixbiopharma.com
Website LinkedIn
Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lead compound LTX-315 provides access to antigens by using the patient’s own tumor as source of antigens and turns cold tumors hot. Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Lytix Biopharma?
Lytix Biopharma has 1 investors on record on gritt.io.
When did Lytix Biopharma last raise funding?
The most recent investment in Lytix Biopharma recorded on gritt.io was in June 2015.
When was Lytix Biopharma founded?
Lytix Biopharma was founded in 2003.
What industry is Lytix Biopharma in?
Lytix Biopharma operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Lytix Biopharma based?
Lytix Biopharma is headquartered in Oslo, Norway.